SUTUREGARD is on a mission to close more wounds simply and safely
, a privately held medical device firm with patented technology that allows surgeons to perform simple closures of high-tension wounds through rapid intraoperative tissue expansion.
Founded in 2015 and based in Portland, Oregon, SUTUREGARD™ Medical, Inc. is a privately held medical device firm with patented technology that allows surgeons to perform simple closures of high-tension wounds through rapid intraoperative tissue expansion. For skin cancer surgeons (Mohs Surgeons), SUTUREGARD’s initial target market, the SUTUREGARD™ device allows closure of wounds using tissue expansion instead of relying on flaps, grafts, or second intent healing. This is particularly useful for scalp and lower leg closures. For some skin cancer surgeons, this will add greater efficiency to their day. For other skin cancer surgeons, this will retain closures in their practice that they would have otherwise sent to other specialists.
The Company founders — a Corvallis, Oregon-based skin cancer (Moh’s) surgeon and his Ph.D. nurse business partner — designed the SUTUREGARD device. The Company invested three years conducting bench research, pre-clinical studies, and customer discovery prior to completion of a successful human use study in 2018.
“SUTUREGARD Medical launched the SUTUREGARD device in November, 2018 at the Fundamentals of Mohs Surgery Conference and the product was enthusiastically received by surgeons.” Dan Ladizinsky, MD, CEO of SUTUREGARD Medical.